% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Stahler:275259,
      author       = {A. Stahler and B. Hoppe and I.-K. Na$^*$ and L. Keilholz
                      and L. Müller and M. Karthaus and S. Fruehauf and U.
                      Graeven and L. Fischer von Weikersthal and E. Goekkurt and
                      S. Kasper$^*$ and A. J. Kind and A. Kurreck and A. H. S.
                      Alig and S. Held and A. Reinacher-Schick and V.
                      Heinemann$^*$ and D. Horst$^*$ and A. Jarosch and S.
                      Stintzing$^*$ and T. Trarbach and D. P. Modest$^*$},
      title        = {{C}onsensus {M}olecular {S}ubtypes as {B}iomarkers of
                      {F}luorouracil and {F}olinic {A}cid {M}aintenance {T}herapy
                      {W}ith or {W}ithout {P}anitumumab in {RAS} {W}ild-{T}ype
                      {M}etastatic {C}olorectal {C}ancer ({P}ana{M}a, {AIO} {KRK}
                      0212).},
      journal      = {Journal of clinical oncology},
      volume       = {41},
      number       = {16},
      issn         = {0732-183X},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2023-00706},
      pages        = {2975-2987},
      year         = {2023},
      note         = {2023 Jun 1;41(16):2975-2987},
      abstract     = {Consensus molecular subtypes (CMSs) were evaluated as
                      prognostic and predictive biomarkers of patients with RAS
                      wild-type metastatic colorectal cancer (mCRC) receiving
                      fluorouracil and folinic acid (FU/FA) with or without
                      panitumumab (Pmab) after Pmab + mFOLFOX6 induction within
                      the randomized phase II PanaMa trial.CMSs were determined in
                      the safety set (ie, patients that received induction) and
                      full analysis set (FAS; ie, randomly assigned patients who
                      received maintenance) and correlated with median
                      progression-free survival (PFS) and overall survival (OS)
                      since the start of induction or maintenance treatment and
                      objective response rates (ORRs). Hazard ratios (HRs) and
                      $95\%$ CI were calculated by univariate/multivariate Cox
                      regression analyses.Of 377 patients of the safety set, 296
                      $(78.5\%)$ had available CMS data: CMS1/2/3/4: 29
                      $(9.8\%)/122$ $(41.2\%)/33$ $(11.2\%)/112$ $(37.8\%)$ and
                      unclassifiable: 17 $(5.7\%).$ The CMSs were prognostic
                      biomarkers in terms of PFS (P < .0001), OS (P < .0001), and
                      ORR (P = .02) since the start of induction treatment. In FAS
                      patients (n = 196), with CMS2/4 tumors, the addition of Pmab
                      to FU/FA maintenance therapy was associated with longer PFS
                      (CMS2: HR, 0.58 $[95\%$ CI, 0.36 to 0.95], P = .03; CMS4:
                      HR, 0.63 $[95\%$ CI, 0.38 to 1.03], P = .07) and OS (CMS2:
                      HR, 0.88 $[95\%$ CI, 0.52 to 1.52], P = .66; CMS4: HR, 0.54
                      $[95\%$ CI, 0.30 to 0.96], P = .04). The CMS interacted
                      significantly with treatment in terms of PFS (CMS2 v CMS1/3:
                      P = .02; CMS4 v CMS1/3: P = .03) and OS (CMS2 v CMS1/3: P =
                      .03; CMS4 v CMS1/3: P < .001).The CMS had a prognostic
                      impact on PFS, OS, and ORR in RAS wild-type mCRC. In PanaMa,
                      Pmab + FU/FA maintenance was associated with beneficial
                      outcomes in CMS2/4, whereas no benefit was observed in
                      CMS1/3 tumors.},
      cin          = {BE01 / MU01 / ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331 / I:(DE-He78)MU01-20160331 /
                      I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37018649},
      doi          = {10.1200/JCO.22.02582},
      url          = {https://inrepo02.dkfz.de/record/275259},
}